Wockhardt is currently trading at Rs 1541.80, down by 1.55 points or 0.10% from its previous closing of Rs. 1543.35 on the BSE.
The scrip opened at Rs. 1539.00 and has touched a high and low of Rs. 1554.00 and Rs. 1519.20 respectively. So far 138276 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 2000.00 on 08-Apr-2015 and a 52 week low of Rs. 583.00 on 18-Jul-2014.
Last one week high and low of the scrip stood at Rs. 1552.00 and Rs. 1456.00 respectively. The current market cap of the company is Rs. 16989.13 crore.
The promoters holding in the company stood at 74.39% while Institutions and Non-Institutions held 11.83 % and 13.64% respectively.
Wockhardt has recalled 1,62,142 cartons of various drugs, which are used to treat ailments like high blood pressure and ulcer, from the US market due to deviations in current good manufacturing practice norms laid down by the American health regulator. As per the US Food and Drug Administration (USFDA), Mumbai-based company has recalled the drugs for current good manufacturing practice (CGMP) deviations.
Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s, the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: